Validation of methodology for assessment of pulmonary function in patients who undergo total laryngectomy

Castro, Mario; Dedivitis, Rogério Aparecido; Salge, João Marcos; Koyama, Leonardo Kenji Sakaue; Cernea, Cláudio Roberto; Brandão, Lenine Garcia

doi:10.1002/hed.24373

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, we observed that pulmonary functions measured by spirometry did not reflect the risk of ILD. Pulmonary functions are thoroughly assessed in patients who will undergo a laryngectomy, and thus our findings are not derived from the insufficiency of the pulmonary function tests …”

Section: Discussionmentioning

confidence: 99%

Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab

et al. 2019

View full text Add to dashboard Cite

Background Interstitial lung disease (ILD) is known as a potentially severe adverse event associated with epidermal growth factor receptor (EGFR)‐targeted therapy. The incidence and risk factors of ILD in patients with head and neck squamous cancer (HNSCC) treated with cetuximab, an anti‐EGFR monoclonal antibody, have not been established. Methods We retrospectively reviewed patients with HNSCC who received cetuximab from December 2012 to December 2016 at our institute and evaluated the incidence and risk factors of ILD. Results Of the 201 patients with HNSCC, ILD was observed in 9 patients (4.5%), 8 of whom had grade 3 or higher. High Krebs von den Lungen‐6 (KL‐6) and ≥50 pack‐years of smoking were significantly predictive of associated with ILD (P = 0.00011 and 0.05, respectively). Conclusion The incidence of ILD in patients with HNSCC treated with cetuximab was <5%, but most of the ILD cases were severe. High KL‐6 and smoking histories might be predictive for ILD among patients with HNSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Several studies evaluated the reproducibility of different extratracheal devices, but detailed analysis in lung function is still lacking. In addition, systems used for this cause often were associated with technical problems, such as leakages, or were uncomfortable for patients . As a result, there is an unmet need for a standardized and simple method for routine use in order to perform reliable lung function tests in laryngectomized patients.…”

Section: Discussionmentioning

confidence: 99%

Short‐term and long‐term follow‐up of pulmonary function in patients with COPD after total laryngectomy: A prospective study

et al. 2017

View full text Add to dashboard Cite

show abstract

Validation of methodology for assessment of pulmonary function in patients who undergo total laryngectomy

Abstract: The methodology for the assessment of the pulmonary function by using the extratracheal proposed device is reliable, accurate, and reproducible. © 2016 Wiley Periodicals, Inc. Head Neck 38: E2030-E2034, 2016.

Cited by 2 publications

References 13 publications

Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab

Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab

Short‐term and long‐term follow‐up of pulmonary function in patients with COPD after total laryngectomy: A prospective study

Contact Info

Product

Resources

About